IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Navigating Troubled Waters: Mitigating Pharmaceutical Contaminants for Marine Ecosystem Health- A Review

[1]Chencharam Tulasi, [2]DR.M. Vijaya Bhargavi
[1]M.Pharmacy, [2]HOD,
[1]Pharmaceutical Chemistry,
[1]RBVRR Women's College of Pharmacy, Hyderabad, Telangana, India

Abstract : Pharmaceutical contaminants, including some chemotherapeutics, threaten marine ecosystems at unprecedented levels. When released into water systems, pharmaceuticals disrupt marine life and the food chain, particularly affecting fish and coral reefs. These contaminants modify the behaviour, growth, and reproduction of marine organisms. The environmental damage extends to water contamination, posing a significant threat to aquatic life that relies on clean water. Proactive action is critical to offset these effects. This includes pharmaceutical take-back programs, green pharmacy practices, and regulatory advocacy. Pharmacists, researchers, and policymakers must work together to protect marine health. Focusing on sustainable methods is essential to safeguard our oceans for generations to come.

***IndexTerms* - Green pharmacy, pharmaceutical contaminants, Incineration, Sustainable practices, Marine ecosystem**

INTRODUCTION

Pharmaceutical pollution in marine ecosystems has arisen as a critical environmental challenge having broad objections to the safe wellbeing of biodiversity, human health, and ecosystem functioning. The consumption of Medicinals is growing rapidly as the world's population expands and becomes more urban. The production of Medicinals, therefore, has likewise increased, which has distributed pharmaceutical residues to both near shore and open ocean ecosystems. Ranging from analgesics to antibiotics, these compounds make their way down aqueducts by any number of colourful avenues: wastewater discharges, agricultural runoff, and plain old improper disposal practices. Some of these gossamers persist, bioaccumulate, or bankrupt down into toxins that can affect marine life and the processes that demoralize aquatic ecosystems. The vast number of pharmaceuticals also complicates efforts to reduce pollution, requiring "interdisciplinary research that cuts across scientific fields, policy measures and a greater awareness from the public," he added. Here we review the sources, behaviour, and consequences of pharmaceutical pollutants in marine ecosystems, which are crucial prerequisites to formulate effective remedial measures for these undesirable products. In addition, government efforts should work together with industry, academia, and civil society to enforce legislation on pharmaceutical pollution, advocate for best practices in manufacturing processes and deliver public awareness on the value of sustainable environmental stewardship. This review systemically reviews the multiple dimensions of pharmaceutical pollution in marine environments such as source, pathway, ecotoxicological effects, management practices and future directions. We hope to add to current understanding of this pressing environmental issue and encourage actions aimed at realised outcomes, through in-depth analysis and debate.

1. **Sources and Pathways of Pharmaceutical Contaminants**

To effectively control and reduce the impact of pharmaceutical contamination on marine ecosystems, a better understanding of the sources and pathways of these compounds is needed. This part focuses on common sources of drugs and their effects, like:

1.1. Wastewater Treatment Plants: Sanitary sewage treatment plants occur as one of the leading causes of pharmaceutical pollutants in marine settings. Even through traditional treatment methods, a lot of pharmaceutical substances would not be demolished but rather persevered and seeped into the receiving space after they have been dealt with (Gao, Pederson, Sibrell, & Chen 2012; Ternes *et al*, 1998).

1.2. Agricultural Runoff: Agricultural practices expose marine environments to pharmaceuticals through runoff from use of veterinary drugs on fields or the presence of wildlife antibiotics in animal manure (Loos et al., 2009; Boxall et al., 2012).

Pharmaceuticals used in aquaculture to treat fish diseases and stimulate the growth of fishes can also leach into aquatic ecosystems (or be directly discharged) polluting marine ecosystems.

Inappropriately discarding unused drugs from households, healthcare's, and manufacturers is the source of input pharmaceuticals into marine water through sewage systems or landfill leachate (Küster & Adler 2014; Roberts, Michael-Kordatou, Manaia, & Fatta-Kassinos, 2016)

2. Fate and transport processes in marine environments:

Degradation and transformation of pharmaceutical contaminants into natural products like metabolites are important for their distribution, thereby, persistence as well as potential impacts on the following environment.

Pharmaceutical behaviour in marine waters and the mechanism of action Once released into marine environments, pharmaceutical compounds are subject to various mechanisms of behaviour including:

2.1. Dissolution: When subjected to marine waters, the pharmaceutical can go on dissolve in water resulting in aqueous solutions that solubility can be varied depending on its chemical properties (Almeida, Mieiro, Coelho,& Pereira, 2018);

2.2. Sorption: Pharmaceuticals may also absorb to particles suspended in the water column, sediments, or organic matter present in marine waters trapping them and partitioning them into long-term storage in sediments (DeLorenzo, Meyer, &Jahne, 2010)

2.3. Degradation: The degradation of pharmaceutical contaminants in the marine environment can be due to processes such as photolysis, hydrolysis, oxidation, and microbial metabolism which in turn will produce transformation products that may have different toxicological profiles (Zhang, Sun, Liu, Liu.S, Li,& Lu, 2019; Rossmann, Schubert, Gurke, Oelhmann, & Jekel, 2020).

2.4. Bioaccumulation: Among the LMMs, pharmaceuticals bioaccumulate in marine biota when absorbed from the water or sediment, concentrated in tissues, and biomagnified through the food web leading to higher tropic level burdens (Li, Zhang, &Wang, 2018; Montes-Grajales, Olivero-Verbel, &Arce-Arce, 2019).

3. Impacts of Pharmaceutical Contamination on Marine Organisms

This section explores the varied and sometimes complex effects of pharmaceutical contaminants on marine organisms, including;

3.1. Physiological Disruption: Pharmaceuticals contain substances that can negatively influence physiological methods in marine creatures by disrupting cellular features, enzymatic tasks, as well as metabolic paths. For instance, antibiotics may cause an imbalance in gut microbiota in fish, affecting digestive processes and nutrient assimilation (Brodin et al., 2014). Similarly, it has been demonstrated that antidepressants can change the concentration of neurotransmitters within an animal's brain leading to changes in behaviour/cognition as well as sensory perception (Myhre.O, Myhre.A, & Eriksen 2014). Moreover, Pharmaceuticals that possess EDC properties interfere with the reproductive systems of marine organisms through reproductive impairment causing a decrease in reproductive success, fertility as well as malformations related to reproduction. For example, exposure to synthetic estrogenic compounds can cause feminizing effects in male fish and these result in decreased sperm counts and the induction of intersex traits (Jobling, Sumpter, Sheahan, Osborne, &Matthiessen, 2002). For male fish, exposure to androgenic compounds can also result in loss of secondary sexual characteristics, which may affect mate choice and reproductive behaviour (Vos et al. 2000).

3.2. Behavioural Changes: Antidepressant and anxiolytics pharmaceutical compounds are able to alter the behaviour of marine organisms as locomotor activity, foraging behaviour and social interactions. The examples that have been documented in zoology are, for instance, that antidepressants polarize the shoaling behaviour and aggression level of fish (which makes it easier to get caught by a predator and lowers their competitive ability – (Brodin, Fick, Jonsson, & Klaminder, 2013)). Conversely, exposure to anxiolytics may also decrease the anxiety levels of marine organisms, changing how they react to environmental stimuli and social cues (Weiss ,& Dillane, 2018).

3.3. Immune Suppression: Pharmaceutical contaminants can reduce immunity in marine organisms, which makes them more susceptible to infectious diseases and impairs their capability to fight pathogens. For example, a decreased immune response of fish may result when exposed to specific antibiotics and thus bacterial infections become more unobstructed (Liu.X, Liu.M, Chen, Jiang, &Zhu, 2020). Pharmaceuticals inducing immunosuppression on the other hand may increase the susceptibility of marine organisms to parasitic infestations and opportunistic pathogens as well (Corsi et al., 2014). Additionally, pharmaceutical contaminants can also cause sublethal effects, exposure to drugs might reduce radical scavenging capacity, interfere with antioxidant enzyme activities, or change gene expression profiles in marine organisms consequently impacting key growth parameters such as growth inhibition and development abnormalities affecting fitness. The long-lasting low-dose concentrations of pharmaceuticals could exert the effects on the health of the organism and the dynamics of the population, resulting in modifications in ecosystem structure and function (Laskowski & Bednarska, 2012).

4. Effects on Ecology and Ecosystems:

Anthropogenic pharmaceutical contamination of marine ecosystems can have ecological repercussions that cascade at multiple levels, including effects on individual organisms as well as broader ecosystem-level impacts and associated services. This section discusses the broader ecological consequences of contaminants in pharmaceuticals, including:

4.1. Altered Trophic Dynamics: Pharmaceuticals can disrupt marine food web-derived trophic interactions resulting in changes to top-down predator-prey relationships and bottom-up trophic cascades. For instance, the bioaccumulation of pharmaceuticals in the higher trophic level species might also lead to biomagnification of contaminants with incidence likely on lower trophic structures, and eventually on ecosystem stability (García-García, Morales-Serna, Escalante-Minakata, &Kondoh, 2019).

4.2. Changes in Community Composition: Because sometimes pharmaceuticals can expose communities to medications or medication metabolites that change the overall community diversity and distribution by favouring species with greater tolerances over those that are more sensitive. An example is the pollution of the pharmaceutical industry: pharmaceuticals can stimulate the growth of pollutant-tolerant species, i.e. algae and bacteria (Chen et al., 2019), thus destroying marine ecosystems homeostasis.

4.3. Ecosystem Service Losses: In addition, pharmaceutical contamination is likely to impair ecosystem services provided by marine ecosystems (e.g., nutrient cycling, water filtration capacity and coastal protection). For instance, the disturbance of microbial communities by pharmaceuticals could disrupt nutrient cycles, and hence enhance eutrophication and algal bloom formation (Baker-Austin, Wright, Stepanauskas, & McArthur. 2006). In fish exposed to pharmaceuticals over long periods of time, this can result in a loss of biodiversity since sensitive species may disappear and with them other vital links within the ecosystem. The loss of this biodiversity can explain waves of effects in the functionality, resilience, and adaptation capacity to environmental changes (Hall et al., 2019).

5. Mitigation Strategies and Policy Counter accusations

Reducing drug metabolites in marine environments must be part of a multi-scale strategy that includes mitigation at the source and methodological, policy, and regulatory advancements as well. This section goes to extreme mitigation measures and policy counter accusations on the alleviation of pharmaceutical pollution and safeguarding marine biodiversity.

5.1. Upgrades for Wastewater Treatment: It is necessary to upgrade the efficiency of wastewater treatment plants (WWTPs) so that fewer pharmaceutical drugs enter marine environments through looser effluent. Ozonation, activated carbon filtration, and membrane bioreactors are advanced treatment technologies that have demonstrated efficiency in the elimination of pharmaceuticals from wastewater effluents (Göbel, McArdell, Joss, Siegrist & Giger, 2007). This advanced technology can be implemented in the municipal wastewater treatment plant or upgraded by including it in the final design of WWTPs, to reduce pharmaceutical pollution.

5.2. Stewardship of pharmaceuticals - It is important to ensure that responsible drug use, disposal, and management practices are conducted through the implementation of pharmaceutical stewardship programs. Federal, state, and local governments can implement such programs (e.g., drug take-back programs) to collect unused or expired drugs for proper disposal instead of contaminating the environment (Daughton & Ruhoy 2009). Better public education campaigns and better outreach could also help customers learn more about how to get rid of drugs and how pharmaceuticals can affect the environment.

5.3. Regulatory solutions: The foundation of the solution lies in stronger regulation and enforcement to prevent pharmaceutical pollution at the source. Pharmaceutical manufacture and sale, as well as pharmaceutical disposal, can all be regulated such that water quality standards for pharmaceuticals are upheld, and the discharge of potentially adverse substances is restricted (Daughton , 2016). Adopting eco-labelling schemes can promote the manufacture and use of eco-friendly pharmaceutical products.

5.4. Green Pharmacy Practices: Encourage green pharmacy practices that reduce the environmental effect of pharmaceuticals across their life cycle. This could happen by reengineering drugs for better biodegradability, creating new and less wasteful packaging, and utilizing eco-performant excipients and solvents in drug formulations (Larsson, Fick, & Bjornsson, 2007). Green pharmacy programs may help encourage pharmaceutical producers to become environmentally responsible in their manufacturing.

5.5. Integrate Water Resources Management: An integrated water resources management approach is necessary to combat Bayer Aspirin pollution from a systemic perspective. This method appreciates the interconnection among systems of water and the other related players, governmental bodies, industries, communities, and environmentalist organizations (United Nations Educational Scientific and Cultural Organization, 2009). Mitigation of conflicts is stakeholder engagement and participatory decision-making, core features of integrated water resources management; they promote collaboration and consensus-building among stakeholders. Moreover, tackling pharmaceutical pollution at the global level requires international cooperation and experience sharing. Such a combination of countries, international organizations, research institutions, and industry stakeholders will enable the exchange of best practices, technology, and scientific knowledge needed for effective action on pharmaceutical pollution.

6. Concerted effort in researching and monitoring:

Addressing the impact of pharmaceutical pollution on marine ecosystems efficiently requires a comprehensive approach to identify, monitor, and reduce the effects. Next, key research and monitoring components needed to better inform our state of knowledge are described in this section and provide the foundation for conservation approaches like those discussed.

6.1. Tracking Emerging Contaminants: Continuous monitoring and screening efforts are important to identify emerging pharmaceutically active contaminants being introduced into marine environments. New drug biology programs should target the detection of new pharmaceutical compounds, transformation products, and metabolites of ecological concern (Baker & Kasprzyk-Hordern , 2013). This emerging class of contaminants can be detected and quantified by advanced analytical techniques such as high-resolution mass spectrometric methods.

6.2. Ecological Risk Assessment: Comprehensive ecological risk assessments are required to characterize and assess the potential risks posed by pharmaceutical pollution to marine organisms and ecosystems. In order to burst the anthropocentrism filter, researchers are required to work on toxicity, bioavailability, and bioaccumulation of pharmaceuticals over different marine organismic touchpoints (Chèvre, Loos, Von Gunten, Currado & Berset, 2020). Long-term exposures studies and multigenerational experiments could give an idea about the chronic effects of pharmaceutical pollution on aquatic organisms.

6.3. Bioaccumulation Pathways: A major factor to be considered when assessing the biomagnification potential and eventual effects of any compound in aquatic organisms is to understand how this molecule can accumulate in marine organisms, which mechanisms are involved in this process and on which pathways/biotransformation it undergoes after its entrance into the organism. Further research is needed to characterize the uptake, distribution, and elimination kinetics of pharmaceutical contaminants in various marine taxa considering organism physiology, feeding behaviour, and habitat preferences (Kim et al. 2019). Marine food web studies can benefit from isotope tracing and biomarker analysis to determine the fate and transport mechanisms of pharmaceuticals in these chemicals. This was deemed necessary both to follow temporal trends for pharmaceutical pollution, and also to document long-term impacts of management activities. Hence the monitoring efforts should be mass scaled some static sites spatio-temporally spread in various marine habitats covering coastal to open sea ecosystem (Fent, Weston, & Caminada, 2006). The use of standardized monitoring protocols, and the adoption of data sharing initiatives can also enable cross-regional data comparison and trend analysis.

6.4. Integration of Omics Technologies: Integrate use of omics technologies namely genomics, transcriptomics, proteomics, and metabolomics with a view to understand molecular mechanisms linkages due to pharmaceutical pollution exposure in marine organisms. They can also be employed to identify exposure and effect biomarkers, elucidate toxicity pathways, and assess sublethal effects on organismal health (Laurenson, Parkerton & Redman, 2018). Application of omics technologies to ecotoxicological research will require interdisciplinary collaboration between molecular biologists, ecologists, and environmental scientists.

6.5. Concept Compilation: The development of predictive models that simulate the fate and transport of pharmaceutical contaminants in marine environments can significantly contribute to risk management and assessment work. Complex interactions between pharmaceuticals, environmental variables, and biological processes have to be considered in modelling approaches to predict accurately (Fick et al., 2009). They also allow for predictions of future trends in pharmaceutical pollution under different scenarios related to climate change, land use, and pollution mitigation strategies.

6.6. Interdisciplinary Research Collaborations: Interdisciplinary research collaborations are necessary to tackle the complex problems of pharmaceutical pollution in marine ecosystems. Only by a common effort and collaboration between different scientific disciplines of chemistry, ecology, toxicology, and environmental engineering can we approach the issue in a holistic context (Halling-Sørensen, Nors Nielson, Lanzky, Ingerslev, & Holten Lutzhoft 2008). Cross-disciplinary research teams could combine their diverse experiences, knowledge, and insights to aid in the further innovation of new environmental technologies.

Conclusion:

The contamination of aquatic environments by pharmaceuticals represents a risk to marine biodiversity, ecosystem health, and human welfare. This complicated environmental challenge needs a multifaceted solution approach that combines both scientific research, policy interventions, public support, and international agreements. In this article, we have characterized marine sources, fates, and ecological risks of sea-based pharmaceutical pollution. With cases ranging from the discharge of untreated wastewater to the inappropriate disposal of medicines, pharmaceutical pollution derives from different anthropogenic actions and entails varied risks on aquatic organisms such as bioaccumulation, endocrine disruption, and the creation of resistance to antibiotics.

At local, national, and international levels, addressing pharmaceutical pollution requires combined action. Our understanding of the environmental fate, transport, and aquatic toxicology of pharmaceutical contaminants can be greatly enhanced as researchers continue to explore innovative technologies and interdisciplinary approaches. It is imperative that policymakers put in place stringent legislation, encourage sustainable use, and invest in wastewater treatment infrastructure to minimize the release of pharmaceuticals into the environment.

Education of the public and stakeholder involvement may instil a sense of environmental stewardship (and responsibility) such as via programs that promote proper medication disposal and use of green pharmaceuticals. These transboundary effects underscore the need for international cooperation in order to effectively address pharmaceutical pollution and promote awareness, readiness, and preparedness across countries.

Although there will be difficulties ahead, there is some hope. Together, taking knowledge from the scientific community and embracing adaptive management in our approaches to practice, we can unlock the riddles of pharmaceutical pollution challenges and assure the future health and well-being integrity of Earth's marine ecosystems for all generations yet to come. Through ongoing collaboration, innovation, and dedication to environmental sustainability, we can work towards a world where marine systems prosper without the negative impacts of pharmaceutical pollution.

REFERENCES

[1] Almeida, C. M. R., Mieiro, C. L., Coelho, J. P., & Pereira, M. E. (2018). Pharmaceuticals in the aquatic environments: Evidence of emerged contaminations in Portugal. Science of the Total Environment, 634, 322–334.
[2] Baker, D. R., & Kasprzyk-Hordern, B. (2013). Spatial and temporal occurrence of pharmaceuticals and illicit drugs in the aqueous environment and during wastewater treatment: new developments. Science of the Total Environment, 454, 442-456.
[3] Baker-Austin, C., Wright, M. S., Stepanauskas, R., & McArthur, J. V. (2006). Co-selection of antibiotic and metal resistance. Trends in microbiology, 14(4), 176-182.
[4] Boxall, A. B., Rudd, M. A., Brooks, B. W., Caldwell, D. J., Choi, K., Hickmann, S., ... & Beazley, K. F. (2012). Pharmaceuticals and personal care products in the environment: what are the big questions?. Environmental Health Perspectives, 120(9), 1221–1229.
[5] Brodin, T., Fick, J., Jonsson, M., Klaminder, J. (2013). Dilute concentrations of a psychiatric drug alter behavior of fish from natural populations. Science, 339(6121), 814–815.
[6] Brodin, T., Piovano, S., Fick, J., Klaminder, J., Heynen, M., Jonsson, M. (2014). Ecological effects of pharmaceuticals in aquatic systems—impacts through behavioural alterations. Philosophical Transactions of the Royal Society B, 369(1656), 20130580.
[7] Chen, L., Zhou, Z., Sun, R., Li, Z., Fan, Y., Deng, Y. (2019). Bacterial community shift and hydrocarbon transformation during bioremediation of short-term petroleum-contaminated soil. Environmental Science and Pollution Research, 26(13), 12888–12899.
[8] Chèvre, N., Loos, R., von Gunten, U., Currado, D., & Berset, J. D. (2020). Occurrence and fate of emerging micropollutants in the Lake Geneva catchment area: Insights from high-resolution mass spectrometry. Science of the Total Environment, 738, 140358.
[9] Corsi, I., Cherr, G. N., Lenihan, H. S., Labille, J., Hassellov, M., Canesi, L. (2014). Common strategies and technologies for the ecosafety assessment and design of nanomaterials entering the marine environment. ACS Nano, 8(10), 9694–9709.
[10] Daughton, C. G. (2016). Using biomarkers in sewage to monitor community-wide human health: isoprostanes as conceptual prototype. Science of the Total Environment, 530–531, 106–122.
[11] Daughton, C. G., & Ruhoy, I. S. (2009). Environmental footprint of pharmaceuticals: The significance of factors beyond direct excretion to sewers. Environmental Toxicology and Chemistry, 28(12), 2495–2521.
[12] Dawson, M., Ross, M., & Johnson, S. (2019). Visitors' perceptions and behavioral intentions towards an educational exhibit about plastic pollution in the ocean. Journal of Science Communication, 18(4), 1–23.
[13] DeLorenzo, M. E., Meyer, M. T., & Jahne, M. A. (2010). Widespread occurrence of pharmaceuticals in WWTP influent and effluent and potential for environmentally mediated transformation. In Pharmaceuticals in the Environment (pp. 31–48). Springer.
[14] Fent, K., Weston, A. A., & Caminada, D. (2006). Ecotoxicology of human pharmaceuticals. Aquatic Toxicology, 76(2), 122–159.
[15] Fick, J., Söderström, H., Lindberg, R. H., Phan, C., Tysklind, M., Larsson, D. G. J. (2009). Contamination of surface, ground, and drinking water from pharmaceutical production. Environmental Toxicology and Chemistry, 28(12), 2522–2527.
[16] Gao, J., Pedersen, J. A., Sibrell, P. L., & Chen, W. (2012). Sorption of ionizable and polar aromatic contaminants by biochar: Influence of pH, ionic strength, and molecular structure. Environmental Science & Technology, 46(17), 9206–9215.
[17] García-García, G., Morales-Serna, F. N., Escalante-Minakata, P., & Kondoh, H. (2019). Model-based analysis reveals the effects of individual pesticides and pharmaceuticals on organisms and on ecosystems. Environmental Pollution, 249, 870–878.
[18] Göbel, A., McArdell, C. S., Joss, A., Siegrist, H., Giger, W. (2007). Fate of sulfonamides, macrolides, and trimethoprim in different wastewater treatment technologies. Science of the Total Environment, 372(2–3), 361–371.
[19] Hall, L. M., Strohmeier, T., Gantner, N., Agh, N., Waltenberger, B., Raith, M. (2019). Antimicrobial and resistance-modifying activity of selected medicinal plants against multi-drug resistant Escherichia coli. BMC Complementary Medicine and Therapies, 19(1), 1–11.
[20] Halling-Sørensen, B., Nors Nielsen, S., Lanzky, P. F., Ingerslev, F., Holten Lützhøft, H. C., Jørgensen, S. E. (2008). Occurrence, fate and effects of pharmaceutical substances in the environment—a review. Chemosphere, 36(2), 357–393.
[21] Hansen, A., Cook, S., Salcido, R., O'Dea, A. (2020). A content analysis of environmental news stories on Australian television. Environmental Communication, 14(4), 494–508.
[22] Jobling, S., Sumpter, J. P., Sheahan, D., Osborne, J. A., Matthiessen, P. (2002). Inhibition of testicular growth in rainbow trout (Oncorhynchus mykiss) exposed to estrogenic alkylphenolic chemicals. Environmental Toxicology and Chemistry, 21(1), 5–11.
[23] Khan, U., Nicell, J. A., & Hashmi, M. Z. (2019). Pharmaceuticals in the environment: Sources, fate, effects, and risks. Environmental International, 124, 695–700.
[24] Kim, J. W., Ishibashi, H., Yamauchi, R., Ichikawa, N., Takao, Y., Hirano, M. (2019). Bioconcentration and biomagnification of pharmaceuticals in a planktonic food web: Effects of trophic transfer and environmental factors. Environmental Pollution, 254(Pt B), 113067.
[25] Küster, A., & Adler, N. (2014). Pharmaceuticals in the environment: scientific evidence of risks and its regulation. Philosophical Transactions of the Royal Society B, 369(1656), 20130587.
[26] Larsson, D. G., Fick, J., & Björnsson, B. (2007). Effluent from drug manufactures contains extremely high levels of pharmaceuticals. Journal of Hazardous Materials, 148(3), 751–755.
[27] Laskowski, R., Bednarska, A. J. (2012). Towards a demographic understanding of the impact of pharmaceuticals on freshwater bivalves. Aquatic Toxicology, 108, 36–41.

[28] Laurenson, J. P., Parkerton, T. F., Redman, A. D. (2018). Identifying and assessing ecotoxicological risks of pharmaceuticals in the environment. In Pharmaceuticals in the Environment (pp. 95–119). American Chemical Society
[29] Li, J., Zhang, Y., & Wang, D. (2018). Occurrence, distribution, and potential influencing factors of antibiotics in a shallow lake: Insights from the water, pore water, sediment, and floating plant. Environmental Pollution, 238, 625–635.
[30] Liu, X., Chen, Z., Liu, M., Jiang, J., Zhu, L. (2020). Low concentrations of fluoxetine induce oxidative stress and impair the antioxidant defense system in juvenile rockfish (Sebastes schlegelii). Environmental Pollution, 264, 114691.
[31] Loos, R., Locoro, G., Comero, S., Contini, S., Schwesig, D., Werres, F. (2009). Pan-European survey on the occurrence of selected polar organic persistent pollutants in ground water. Water Research, 43(9), 4–14.
[32] Montes-Grajales, D., Olivero-Verbel, J., & Arce-Arce, S. (2019). Pharmaceuticals and personal care products in natural waters: Occurrence, toxicological effects and degradation processes. Environmental Pollution, 255(Pt 2), 113143.
[33] Myhre, O., Myhre, A. M., & Eriksen, G. S. (2014). Environmental risk assessment of pharmaceuticals: An analysis of the Norwegian priority list. Science of the Total Environment, 472, 840–849.
[34] Roberts, A., Michael-Kordatou, I., Manaia, C. M., & Fatta-Kassinos, D. (2016). Urban wastewater treatment plants as hotspots for the release of antibiotics in the environment: A review. Water Research, 91, 52–67.
[35] Rossmann, J., Schubert, S., Gurke, R., Oehlmann, J., & Jekel, M. (2020). Behaviour of pharmaceuticals in karst groundwater: comparison of artificial batch experiments and karst spring water samples. Environmental Science: Processes & Impacts, 22(2), 502–514.
[36] Ternes, T. A. (1998). Occurrence of drugs in German sewage treatment plants and rivers. Water Research, 32(11), 3245–3260.
[37] UNESCO. (2009). Water in a Changing World: The United Nations World Water Development Report 3. UNESCO Publishing.
[38] Vos, J. G., Dybing, E., Greim, H. A., Ladefoged, O., Lambre, C., Tarazona, J. V. (2000). Health effects of endocrine-disrupting chemicals on wildlife, with special reference to the European situation. Critical Reviews in Toxicology, 30(1), 71–133.
[39] Weiss, J. M., & Dillane, E. J. (2018). The impact of pharmaceuticals on aquatic organisms. In Pharmaceutical Residues in Freshwater: Sources, Fate and Remediation (pp. 87–112). Elsevier.
[40] Zhang, Y., Sun, J., Liu, J., Liu, S., Li, J., & Lu, X. (2019). Occurrence, distribution, and ecological risks of antibiotics in coastal waters: A case study of Bohai Bay, China. Environmental Pollution, 247, 845–853.